These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 35015587)

  • 1. Indication-Specific Generic Uptake of Imatinib Demonstrates the Impact of Skinny Labeling.
    Walsh BS; Kesselheim AS; Sarpatwari A; Rome BN
    J Clin Oncol; 2022 Apr; 40(10):1102-1110. PubMed ID: 35015587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia.
    Lejniece S; Udre I; Rivkina A
    Exp Oncol; 2017 Jul; 39(2):151-154. PubMed ID: 29483494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initiation of generic imatinib may improve medication adherence for patients with chronic myeloid leukemia.
    Cole AL; Jazowski SA; Dusetzina SB
    Pharmacoepidemiol Drug Saf; 2019 Nov; 28(11):1529-1533. PubMed ID: 31507005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expenditures for First- and Second-Generation Tyrosine Kinase Inhibitors Before and After Transition of Imatinib to Generic Status.
    Kenzik KM; Bhatia R; Bhatia S
    JAMA Oncol; 2020 Apr; 6(4):542-546. PubMed ID: 31999305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Efficacy of Generic Imatinib as First- and Second-line Therapy: 3-Year Follow-up of Patients With Chronic Myeloid Leukemia.
    Islamagic E; Hasic A; Kurtovic S; Suljovic Hadzimesic E; Mehinovic L; Kozaric M; Kurtovic-Kozaric A
    Clin Lymphoma Myeloma Leuk; 2017 Apr; 17(4):238-240. PubMed ID: 28283298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.
    Padula WV; Larson RA; Dusetzina SB; Apperley JF; Hehlmann R; Baccarani M; Eigendorff E; Guilhot J; Guilhot F; Hehlmann R; Mahon FX; Martinelli G; Mayer J; Müller MC; Niederwieser D; Saussele S; Schiffer CA; Silver RT; Simonsson B; Conti RM
    J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26944912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs.
    Erçalışkan A; Seyhan Erdoğan D; Eşkazan AE
    Blood Adv; 2021 Sep; 5(17):3344-3353. PubMed ID: 34477815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors.
    Rubin JL; Taylor DC; Sanon M; Coombs JH; Bollu VK
    J Manag Care Pharm; 2010 Sep; 16(7):482-91. PubMed ID: 20726677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States.
    Abou Dalle I; Kantarjian H; Burger J; Estrov Z; Ohanian M; Verstovsek S; Ravandi F; Borthakur G; Garcia-Manero G; Jabbour E; Cortes J
    Cancer Med; 2019 Nov; 8(15):6559-6565. PubMed ID: 31502383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU.
    Conti RM; Padula WV; Larson RA
    Ann Hematol; 2015 Apr; 94 Suppl 2(0 2):S249-57. PubMed ID: 25814091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
    Deremer DL; Ustun C; Natarajan K
    Clin Ther; 2008 Nov; 30(11):1956-75. PubMed ID: 19108785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generic formulations of imatinib for treatment of Philadelphia chromosome-positive leukemia in pediatric patients.
    Suttorp M; Metzler M; Millot F; Shimada H; Bansal D; Günes AM; Kalwak K; Sedlacek P; Baruchel A; Biondi A; Hijiya N; Schultz KR; Schrappe M
    Pediatr Blood Cancer; 2018 Dec; 65(12):e27431. PubMed ID: 30160364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
    Cohen MH; Johnson JR; Pazdur R
    Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Branded and Generic Imatinib Plasma Concentrations in Patients With Chronic Myelogenous Leukemia: Unicentric Study.
    Ostojic A; Sertic D; Roncevic P; Peric Z; Granic P; Matic N; Basic-Kinda S; Serventi-Seiwerth R; Radman I; Zadro R; Nemet D
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):472-6. PubMed ID: 27245313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Realized and Projected Cost-Savings from the Introduction of Generic Imatinib Through Formulary Management in Patients with Chronic Myelogenous Leukemia.
    Campbell D; Blazer M; Bloudek L; Brokars J; Makenbaeva D
    Am Health Drug Benefits; 2019 Nov; 12(7):333-342. PubMed ID: 32055281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors.
    Teng JF; Mabasa VH; Ensom MH
    Ther Drug Monit; 2012 Feb; 34(1):85-97. PubMed ID: 22215488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of generic and original imatinib in the treatment of newly diagnosed patients with chronic myelogenous leukemia in chronic phase: a multicenter retrospective clinical study].
    Jiang H; Zhi LT; Hou M; Wang JX; Wu DP; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2017 Jul; 38(7):566-571. PubMed ID: 28810322
    [No Abstract]   [Full Text] [Related]  

  • 18. Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability.
    Widmer N; Decosterd LA; Leyvraz S; Duchosal MA; Rosselet A; Debiec-Rychter M; Csajka C; Biollaz J; Buclin T
    Br J Cancer; 2008 May; 98(10):1633-40. PubMed ID: 18475296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of the efficacy and safety of Chinese generic imatinib and branded imatinib in patients with chronic myeloid leukemia in consideration of demographic characteristics].
    Dou XL; Yu L; Qin YZ; Shi HX; Lai YY; Hou Y; Huang XJ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):924-931. PubMed ID: 31856442
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparable Efficacy and Safety of Generic Imatinib and Branded Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia With a Consideration of Socioeconomic Characteristics: A Retrospective Study From a Single Center.
    Dou X; Qin Y; Lai Y; Shi H; Huang X; Jiang Q
    Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):e304-e315. PubMed ID: 32209331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.